by Michael R. DeBaun, and Ellen Wright Clayton

Slides:

Advertisements

Similar presentations

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease by Monica L. Hulbert,

Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle.

Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia by Stella T. Chou, Jonathan M. Flanagan, Sunitha.

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

Gupta V, Tallman MS, Weisdorf DJ

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Nonmyeloablative conditioning for relapsed follicular lymphoma

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival by Monika Führer, Udo Rampf, Irith Baumann, Andreas.

Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients by Oluwagbemiga O. Ayoola, Rahman A.

by Adetola A. Kassim, Amanda B. Payne, Mark Rodeghier, Eric A

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Stage C or not stage C…? by Claire Dearden Blood

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

by Michael F. Leahy, and J. Harvey Turner

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Sabina Kersting, Leo F. Verdonck

Activity of eltrombopag in severe aplastic anemia

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

A Population-Based Cohort Study of Late Mortality in Adult Autologous Hematopoietic Stem Cell Transplant Recipients in Australia Lesley J. Ashton, Renate.

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

Where there’s a will, there’s a way: establishing hematopoietic stem cell transplantation in Myanmar by Aye Aye Gyi, Rai Mra, Htun Lwin Nyein, Thida Aung,

MRI in sickle cell disease.

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)‏ by Ahmed A. Daak, Carlton D. Dampier, Beng.

by Alex Aleshin, and Peter L. Greenberg

Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases by John A. Snowden, Manuela Badoglio,

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea by Françoise Bernaudin, Cécile Arnaud,

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Robert.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Volume 2(Supplement 1):1-3

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children Xiaojun.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

by Christine L. Kempton, and Amanda B. Payne

Volume 2(Supplement 1):46-49

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study by Hesham M. Eissa, Lu Lu, Malek Baassiri,

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

The journey of stem cell transplantation in Bangladesh: a hike to the state of the art with collaboration between DMCH and MGH by Mafruha Akter, Mohiuddin.

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells by Yi-Bin Chen, Jennifer Le-Rademacher,

Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the.

Resistance mechanism for ibrutinib in marginal zone lymphoma

Effect of donor and recipient CMV serostatus on survival after HSCT in 2 large cohorts. Effect of donor and recipient CMV serostatus on survival after.

by Andrew L. Gilman, Michael J

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

by Lucy A. Godley, and Akiko Shimamura

Survival of children with sickle cell disease

by Jan J. Cornelissen, and Didier Blaise

Volume 2(Supplement 1):4-7

Presentation transcript:

by Michael R. DeBaun, and Ellen Wright Clayton Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease by Michael R. DeBaun, and Ellen Wright Clayton BloodAdv Volume 1(26):2568-2571 December 12, 2017 © 2017 by The American Society of Hematology

Estimated childhood for survival for children with SCA based on therapy. Estimated childhood for survival for children with SCA based on therapy. Hypothetical cohort of 1000 children with SCA followed for 15 years receiving either HU therapy (children with severe disease) or HSCT. Mortality rates are based on the Belgium cohort study.10 Michael R. DeBaun, and Ellen Wright Clayton Blood Adv 2017;1:2568-2571 © 2017 by The American Society of Hematology